-
1
المؤلفون: Hugh Kilpatrick, Z. A. Bascal, Peter Czuczman, Alban Denys, Andrew L. Lewis, Rhys Whomsley, David Grey
المصدر: Theranostics, vol. 7, no. 8, pp. 2164-2176
مصطلحات موضوعية: business.industry, Metabolite, medicine.medical_treatment, Cmax, Medicine (miscellaneous), Pharmacology, Vandetanib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine.anatomical_structure, chemistry, Pharmacokinetics, Animals, Contrast Media/administration & dosage, Contrast Media/adverse effects, Contrast Media/pharmacokinetics, Embolization, Therapeutic/methods, Injections, Intra-Arterial, Liver/diagnostic imaging, Liver/pathology, Models, Animal, Piperidines/administration & dosage, Piperidines/adverse effects, Piperidines/pharmacokinetics, Quinazolines/administration & dosage, Quinazolines/adverse effects, Quinazolines/pharmacokinetics, Radiography, Abdominal, Swine, Tomography, X-Ray Computed, Vandetanib-eluting Radiopaque Beads, pharmacokinetics, safety and toxicity, 030220 oncology & carcinogenesis, Toxicity, Medicine, Distribution (pharmacology), 030211 gastroenterology & hepatology, Embolization, business, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), medicine.drug, Artery
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c26d962737625d69577515e2d40c2ea1
https://doi.org/10.7150/thno.19652 -
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3
المؤلفون: Andrea Varga, Antoine Hollebecque, Rastilav Bahleda, Anas Gazzah, Christophe Massard, Sandrine Aspeslagh, Jean-Charles Soria, Anna Spreafico, Michele Reni, Kunwar Shailubhai
المساهمون: Medical Oncology
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Antimetabolites, Antineoplastic/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Toxicology, Deoxycytidine, Gastroenterology, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Drug Interactions, Middle Aged, Cyclin-Dependent Kinases, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Peritoneal mesothelioma, Female, medicine.drug, Antimetabolites, Antineoplastic, medicine.medical_specialty, Maximum Tolerated Dose, Neutropenia, Cyclin-Dependent Kinases/antagonists & inhibitors, 03 medical and health sciences, Refractory, Pharmacokinetics, Internal medicine, medicine, Humans, Lung Neoplasms/drug therapy, Deoxycytidine/administration & dosage, Aged, Pharmacology, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, medicine.disease, Pyrazoles/administration & dosage, Gemcitabine, Quinazolines/administration & dosage, Neoplasms/drug therapy, Regimen, 030104 developmental biology, Drug Resistance, Neoplasm, Concomitant, Quinazolines, Pyrazoles, business
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42306b90b467bedc036686d59e41b35d
https://hdl.handle.net/20.500.14017/91e1653b-3c7b-4d0b-abd1-66ca3def9be4 -
4
المؤلفون: Holger Eidtmann, Evandro de Azambuja, Geraldine Gebhart, Catherine E. Ellis, Hatem A. Azim, Hervé Cure, Marion Maetens, Peter Vuylsteke, Michail Ignatiadis, Ghizlane Rouas, Julien Domont, Malcolm Bavington, Claudia Aura, Serena Di Cosimo, Antonella Ferro, Christos Sotiriou, Cristina Gamez, Juan Carlos Toral-Peña, Martine Piccart-Gebhart, José Baselga, Françoise Rothé
المصدر: Breast, 22 (6
مصطلحات موضوعية: Receptor, ErbB-2, medicine.medical_treatment, Gastroenterology, Targeted therapy, chemistry.chemical_compound, Circulating tumor cell, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized -- administration & dosage, skin and connective tissue diseases, Neoadjuvant therapy, Aged, 80 and over, General Medicine, Middle Aged, Neoplastic Cells, Circulating, Neoadjuvant Therapy, Paclitaxel -- administration & dosage, Paclitaxel, Chemotherapy, Adjuvant, Breast Neoplasms -- chemistry -- drug therapy -- pathology, Female, medicine.drug, Receptor, ErbB-2 -- analysis -- antagonists & inhibitors, Adult, medicine.medical_specialty, Breast Neoplasms, Quinazolines -- administration & dosage, Antibodies, Monoclonal, Humanized, Lapatinib, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Young Adult, Breast cancer, Internal medicine, mental disorders, medicine, Neoplastic Cells, Circulating -- chemistry -- pathology, Humans, In patient, neoplasms, Aged, Gynecology, business.industry, Médecine pathologie humaine, medicine.disease, Sciences biomédicales, Cancérologie, chemistry, Quinazolines, Surgery, business
وصف الملف: 2 full-text file(s): application/pdf; application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::762fb130005a634adcc13840b62694c1
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/157832 -
5
المؤلفون: Joel Miller, Antoine Hollebecque, Antoine Italiano, Karim A. Benhadji, Christophe Massard, Nadine Houede, Jean-Charles Soria, Ezra E.W. Cohen, Paul Westwood, Les H. Brail, William Bumgardner
المساهمون: Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Institut Gustave Roussy (IGR), Oncologie digestive, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Bergonié [Bordeaux], UNICANCER, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de radiothérapie [Gustave Roussy]
المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2014, 50, pp.876--84. ⟨10.1016/j.ejca.2013.12.006⟩مصطلحات موضوعية: Oncology, Male, Cancer Research, Time Factors, Pharmacology, Pyrazoles/administration & dosage/adverse effects/pharmacokinetics, 70-kDa/*antagonists & inhibitors/metabolism, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Proto-Oncogene Proteins c-akt/metabolism, Medicine, Fatigue, Clotting factor, Signal Transducing/metabolism, Adaptor Proteins, Ribosomal Protein S6 Kinases, 70-kDa, Common Terminology Criteria for Adverse Events, Vomiting/chemically induced, Middle Aged, 3. Good health, Anorexia, Treatment Outcome, Area Under Curve, Fatigue/chemically induced, Vomiting, Diarrhea/chemically induced, Female, Erlotinib, medicine.symptom, Drug, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Nausea, Metabolic Clearance Rate, Quinazolines/administration & dosage/adverse effects, [SDV.CAN]Life Sciences [q-bio]/Cancer, Anorexia/chemically induced, Drug Administration Schedule, Dose-Response Relationship, Neoplasms/*drug therapy/metabolism/pathology, effects/pharmacokinetics/*therapeutic use, Erlotinib Hydrochloride, Pharmacokinetics, Internal medicine, Humans, effects/pharmacokinetics, Everolimus, Adverse effect, Protein Kinase Inhibitors/administration & dosage/adverse, Protein Kinase Inhibitors, Adaptor Proteins, Signal Transducing, Aged, Pyrimidines/administration & dosage/adverse effects/pharmacokinetics, Sirolimus, Dose-Response Relationship, Drug, business.industry, Ribosomal Protein S6 Kinases, Sirolimus/administration & dosage/adverse effects/analogs & derivatives, Pyrimidines, Antineoplastic Combined Chemotherapy Protocols/adverse, Quinazolines, Pyrazoles, business, Proto-Oncogene Proteins c-akt
-
6
المؤلفون: Luc Dirix, Jacques De Greve, Walter Jonat, Martina Uttenreuther-Fischer, Matthias W. Beckmann, Nadia Harbeck, Martin Schuler, Frank Fleischer, Jean-Luc Canon, Peter A. Fasching, Patrick Neven, Jochen Schütte, Ahmad Awada, Philipp Harter, Sven Wind, Marcus Schmidt, Martine Piccart, T. Besse-Hammer, Kurt Possinger, Nina Gottschalk
المساهمون: Laboratory for Medical and Molecular Oncology
المصدر: Breast Cancer Research and Treatment
Breast cancer research and treatment, 134 (3مصطلحات موضوعية: Oncology, Cancer Research, Receptor, ErbB-2, Afatinib, Medizin, Phases of clinical research, EGFR TKI, Quinazolines -- administration & dosage -- adverse effects -- therapeutic use, Cohort Studies, tyrosine kinase inhibitors, cetuximab, Clinical endpoint, Tumor Markers, Biological -- metabolism, Neoplasm Metastasis, skin and connective tissue diseases, Triple-negative breast cancer, estrogen-receptor, Aged, 80 and over, basal-like phenotype, Middle Aged, Metastatic breast cancer, Clinical Trial, Treatment Outcome, Response Evaluation Criteria in Solid Tumors, ADVANCED SOLID TUMORS, Cohort, Female, medicine.drug, Receptor, erbB-2 -- deficiency -- metabolism, Adult, medicine.medical_specialty, EGFR, Antineoplastic Agents, Breast Neoplasms, Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology, Breast cancer, ERBB2 expression, Internal medicine, HER2, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Antineoplastic Agents -- adverse effects -- pharmacology -- therapeutic use, medicine.disease, Survival Analysis, HER2-negative breast cancer, Cancérologie, lung cancer, Quinazolines, Protein Kinase Inhibitors -- adverse effects -- pharmacology -- therapeutic use, business, GROWTH-FACTOR RECEPTOR
وصف الملف: 1 full-text file(s): application/pdf
-
7
المؤلفون: Fountzilas, George, Pectasides, Dimitrios, Kalogera-Fountzila, Anna, Skarlos, Dimosthenis V., Kalofonos, H. P., Papadimitriou, C., Bafaloukos, Dimitrios, Lambropoulos, S., Papadopoulos, S., Kourea, H., Markopoulos, C., Linardou, H., Mavroudis, D., Briassoulis, E. Ch, Pavlidis, Nicholas, Razi, E. D., Kosmidis, Paraskevas A., Gogas, H.
المساهمون: Pavlidis, Nicholas [0000-0002-2195-9961], Kalogera-Fountzila, Anna [0000-0002-6801-3129], Kalofonos, H. P. [0000-0002-3286-778X]
المصدر: Breast cancer research and treatment
مصطلحات موضوعية: Oncology, Cancer Research, Peripheral neuropathy, medicine.medical_treatment, Cancer staging, Carboplatin, chemistry.chemical_compound, Cancer growth, Iressa, Breast cancer, Epidermal growth factor receptor kinase inhibitor, Controlled clinical trial, Antineoplastic Combined Chemotherapy Protocols, Informed consent, Treatment outcome, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Middle aged, Fatigue, Priority journal, Area under the curve, Anemia, Nausea, Gefitinib, Middle Aged, Arthralgia, Immunohistochemistry, Anorexia, Clinical trial, Epidermal growth factor receptor kinase, Treatment Outcome, Advanced breast cancer, Female, Infection, Age distribution, medicine.drug, Human, Drug hypersensitivity, Diarrhea, Adult, medicine.medical_specialty, Neutropenia, Paclitaxel, Vomiting, Cyclin dependent kinase inhibitor 1b, Breast Neoplasms, Major clinical study, Article, Internal medicine, Paclitaxel/administration & dosage, Antineoplastic combined chemotherapy protocols, Rash, medicine, Humans, Phase 2 clinical trial, Tumor biopsy, Aged, Neoplasm Staging, Chemotherapy, Breast Neoplasms/*drug therapy/pathology, Stomatitis, Performance status, business.industry, Cancer, Carboplatin/administration & dosage, Alopecia, Myalgia, Phase 1 clinical trial, medicine.disease, Thrombocytopenia, Quinazolines/administration & dosage, Regimen, Drug efficacy, chemistry, Cytopenia, Neoplasm staging, Cancer adjuvant therapy, Quinazolines, Breast neoplasms, business, Controlled study, Constipation
-
8
المؤلفون: Herlinde Dumez, Martina Uttenreuther-Fischer, Pascal Wolter, T. Besse-Hammer, Patrick Schöffski, Frank Fleischer, Ahmad Awada, Peter Stopfer, Alain Hendlisz, Martine Piccart
المصدر: Investigational New Drugs
Investigational new drugs, 31 (3مصطلحات موضوعية: Oncology, Male, Gastrointestinal Diseases, Afatinib, Tyrosine kinase inhibitor, LINES, Docetaxel, Pharmacology, PACLITAXEL, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects -- pharmacokinetics, Quinazolines -- administration & dosage -- adverse effects -- pharmacokinetics, Neoplasms, Phase I Studies, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Pharmacology & Pharmacy, Stomatitis, Middle Aged, Rash, Skin Diseases -- chemically induced, Toxicity, Taxoids -- administration & dosage -- adverse effects -- pharmacokinetics, BIBW-2992, TRIAL, Female, Taxoids, medicine.symptom, Life Sciences & Biomedicine, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics, BIBW 2992, Maximum Tolerated Dose, CELL LUNG-CANCER, ERLOTINIB, Antineoplastic Agents, Skin Diseases, Drug Administration Schedule, GEFITINIB, Phase I, Pharmacokinetics, Gastrointestinal Diseases -- chemically induced, Internal medicine, medicine, Humans, Adverse effect, neoplasms, Aged, CARBOPLATIN, Science & Technology, business.industry, Epidermal growth factor receptor, KINASE INHIBITOR, medicine.disease, Cancérologie, Neoplasms -- blood -- drug therapy, Clinical trial, Quinazolines, business
وصف الملف: Print-Electronic; 1 full-text file(s): application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed9ba982df0332356cd898f91dd30e4
-
9مورد إلكتروني
المصدر: European journal of cancer, 89
مصطلحات الفهرس: Cancérologie, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast -- diagnostic imaging, Breast Neoplasms -- chemistry -- diagnostic imaging -- drug therapy -- mortality, Female, Humans, Lapatinib, Mammography, Middle Aged, Neoadjuvant Therapy, Quinazolines -- administration & dosage -- therapeutic use, Receptor, ErbB-2 -- analysis, Trastuzumab -- administration & dosage -- therapeutic use, Breast ultrasound, HER2 positive breast cancer, Neoadjuvant, Targeted therapy, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
https://dipot.ulb.ac.be/dspace/bitstream/2013/263246/1/Elsevier_246873.pdf http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/263246 http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL -
10مورد إلكتروني
المصدر: Cancer treatment reviews, 57
مصطلحات الفهرس: Cancérologie, Imagerie médicale, radiologie, tomographie, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- enzymology -- immunology -- pathology, Chemotherapy, Adjuvant, Female, Humans, Lapatinib, Lymphocytes, Tumor-Infiltrating -- drug effects -- immunology -- pathology, Neoadjuvant Therapy, Quinazolines -- administration & dosage, Randomized Controlled Trials as Topic, Receptor, ErbB-2 -- antagonists & inhibitors -- biosynthesis, Trastuzumab -- administration & dosage, HER2-postive breast cancer, Neoadjuvant treatment, Pathologic complete response, Trastuzumab, Tumor-infiltrating lymphocytes, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
https://dipot.ulb.ac.be/dspace/bitstream/2013/253181/1/Elsevier_236808.pdf http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/253181 http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Full Text via ClinicalKey